Amneal Pharmaceuticals, Inc.AMRXEarnings & Financial Report
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Revenue
$702.5M
Gross Profit
$269.6M
Operating Profit
$88.8M
Net Profit
$-156.0K
Gross Margin
38.4%
Operating Margin
12.6%
Net Margin
-0.0%
YoY Growth
13.3%
EPS
$0.00
Amneal Pharmaceuticals, Inc. Q3 FY2024 Financial Summary
Amneal Pharmaceuticals, Inc. reported revenue of $702.5M (up 13.3% YoY) for Q3 FY2024, with a net profit of $-156.0K (down 101.0% YoY) (-0.0% margin). Cost of goods sold was $432.9M, operating expenses totaled $180.7M.
Key Financial Metrics
| Total Revenue | $702.5M |
|---|---|
| Net Profit | $-156.0K |
| Gross Margin | 38.4% |
| Operating Margin | 12.6% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Amneal Pharmaceuticals, Inc. Q3 FY2024 revenue of $702.5M breaks down across 14 segments, led by Other at $137.9M (19.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $137.9M | 19.6% |
| Hormonal Allergy | $132.6M | 18.9% |
| Central Nervous System | $109.0M | 15.5% |
| Distribution Service | $101.6M | 14.5% |
| Oncology | $44.5M | 6.3% |
| Government Label | $41.9M | 6.0% |
| Other Therapeutic Classes | $38.7M | 5.5% |
| Cardiovascular System | $36.4M | 5.2% |
| Dermatology | $19.3M | 2.7% |
| Gastroenterology | $14.5M | 2.1% |
| Metabolic Disease Endocrine | $8.6M | 1.2% |
| Generics Segment | $4.5M | 0.6% |
| Antiviral | $4.4M | 0.6% |
| License Agreement | $2.0M | 0.3% |
Amneal Pharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Amneal Pharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Hormonal Allergy) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Other | — | $33.6M | $21.0M | — |
| Hormonal Allergy | — | $47.6M | $37.7M | $35.4M |
| Central Nervous System | — | $104.8M | $77.6M | $83.4M |
| Distribution Service | — | $107.7M | $96.2M | $99.7M |
Amneal Pharmaceuticals, Inc. Annual Revenue by Year
Amneal Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.0B).
| Year | Annual Revenue |
|---|---|
| 2025 | $3.0B |
| 2024 | $2.8B |
| 2023 | $2.4B |
| 2022 | $2.2B |
Amneal Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Amneal Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $722.5M | +3.9% | $78.0M | 10.8% |
| Q4 FY2025 | $814.3M | +11.5% | $35.1M | 4.3% |
| Q3 FY2025 | $784.5M | +11.7% | $2.4M | 0.3% |
| Q2 FY2025 | $724.5M | +3.2% | $22.4M | 3.1% |
| Q1 FY2025 | $695.4M | +5.5% | $12.2M | 1.8% |
| Q4 FY2024 | $730.5M | +18.4% | $-31.1M | -4.3% |
| Q3 FY2024 | $702.5M | +13.3% | $-156.0K | -0.0% |
| Q2 FY2024 | $701.8M | +17.1% | $6.0M | 0.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $701.8M | $702.5M | $730.5M | $695.4M | $724.5M | $784.5M | $814.3M | $722.5M |
| YoY Growth | 17.1% | 13.3% | 18.4% | 5.5% | 3.2% | 11.7% | 11.5% | 3.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.51B | $3.46B | $3.50B | $3.37B | $3.42B | $3.60B | $3.68B | $3.54B |
| Liabilities | $3.57B | $3.55B | $3.61B | $3.50B | $3.53B | $3.71B | $3.75B | N/A |
| Equity | $-57.5M | $-93.4M | $-109.3M | $-131.7M | $-112.1M | $-109.5M | $-70.8M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $39.7M | $141.8M | $118.1M | $7.4M | $83.8M | $118.5M | $130.3M |